Should You Be Pleased About The CEO Pay At Aarti Drugs Limited's (NSE:AARTIDRUGS)

Simply Wall St
0
In this article:

Prakash Patil is the CEO of Aarti Drugs Limited (NSE:AARTIDRUGS). This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Then we'll look at a snap shot of the business growth. And finally we will reflect on how common stockholders have fared in the last few years, as a secondary measure of performance. This process should give us an idea about how appropriately the CEO is paid.

View our latest analysis for Aarti Drugs

How Does Prakash Patil's Compensation Compare With Similar Sized Companies?

At the time of writing, our data says that Aarti Drugs Limited has a market cap of ₹12b, and reported total annual CEO compensation of ₹15m for the year to March 2019. We think total compensation is more important but we note that the CEO salary is lower, at ₹6.9m. As part of our analysis we looked at companies in the same jurisdiction, with market capitalizations of ₹7.1b to ₹28b. The median total CEO compensation was ₹20m.

So Prakash Patil receives a similar amount to the median CEO pay, amongst the companies we looked at. Although this fact alone doesn't tell us a great deal, it becomes more relevant when considered against the business performance.

You can see a visual representation of the CEO compensation at Aarti Drugs, below.

NSEI:AARTIDRUGS CEO Compensation, November 9th 2019
NSEI:AARTIDRUGS CEO Compensation, November 9th 2019

Is Aarti Drugs Limited Growing?

Over the last three years Aarti Drugs Limited has grown its earnings per share (EPS) by an average of 9.6% per year (using a line of best fit). Its revenue is up 26% over last year.

It's great to see that revenue growth is strong. With that in mind, the modestly improving EPS seems positive. I wouldn't say this is necessarily top notch growth, but it is certainly promising. It could be important to check this free visual depiction of what analysts expect for the future.

Has Aarti Drugs Limited Been A Good Investment?

Given the total loss of 15% over three years, many shareholders in Aarti Drugs Limited are probably rather dissatisfied, to say the least. So shareholders would probably think the company shouldn't be too generous with CEO compensation.

In Summary...

Prakash Patil is paid around what is normal the leaders of comparable size companies.

The per share growth could be better, in our view. And shareholder returns have been disappointing over the last three years. So many would argue that the CEO is certainly not underpaid. CEO compensation is one thing, but it is also interesting to check if the CEO is buying or selling Aarti Drugs (free visualization of insider trades).

Arguably, business quality is much more important than CEO compensation levels. So check out this free list of interesting companies, that have HIGH return on equity and low debt.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.

Advertisement

Recommended Stories

  • Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

    The popular growth investor added to these three existing positions on Tuesday.

  • Here's Exactly When Social Security Recipients Can Expect Benefit Cuts, According to the Latest Trustees Report

    Social Security payments may be subject to cuts. Here's what the timing looks like.

  • Morgan Stanley Predicts up to 110% Rally for These 2 ‘Strong Buy’ Stocks

    Uncertainty is the word of the day, in reference to the near-term economic future. Sentiment will hinge on the inflation numbers due out next week. March’s figure rose to 3.5%, and April’s job numbers showed a marked slowing in the labor market; that combination has stoked fears of stagflation. But – corporate earnings from Q1 are beating expectations, and the stock market has taken a turn for the better with the S&P 500 closing just below 5,200 yesterday. Economic strategists are still optimist

  • Can I Use My RMDs to Transfer Money Into My Roth IRA?

    If you're taking a required minimum distribution from an IRA, 401(k) or other tax-deferred account and don't need the money to cover living expenses, where should you stash that unneeded cash? Investors now need to start taking RMDs at age 73 or, if they were born after 1960, at age 75. Depending on the balances of […] The post Can I Use My RMDs to Transfer Money Into My Roth IRA? appeared first on SmartReads by SmartAsset.

  • How Much Cash Can A $300,000 Annuity Generate For Me Each Month?

    Imagine having a reliable source of income you can count on throughout your retirement. That’s the promise of an annuity. These insurance products have been designed to turn your savings into a steady stream of monthly payments. They guarantee peace of mind and financial security in your golden years. Don't Miss: Are you rich? Here’s what Americans think you need to be considered wealthy. Can you guess how many Americans successfully retire with $1,000,000 saved? The percentage may shock you. An

  • 3 Ridiculously Undervalued Stocks to Buy Hand Over Fist Right Now in May

    Investing in cheap stocks brings unique risks because there is usually a reason the companies are undervalued.

  • Stocks could tank after an ill-advised 'melt-up' if the Fed cuts rates to avoid recession

    "Investors' expectation that the Fed would nip a recession in the bud by easing means that the Fed Put is back," Ed Yardeni said.

  • Pfizer Stock Is Near An 11-Year Low — But Is It A Buy On This 'Massive' Upside?

    Pfizer stock ran up to its 50-day line after the company reported better-than-expected sales and profit. Is PFE stock a buy?

  • Real Estate Developer Soaked by Multimillion Dollar Loss on San Francisco Office Building

    Real estate developer Clarion Properties took a $60 million loss on a San Francisco office building it bought five years ago. The property at 410 Townsend Street is a four-story, 76,000-square-foot building. During the halcyon days of the tech industry, 410 Townsend was known as a startup village and was valued at $1,100 per square foot. That adds up to $86 million, which is what Clarion Partners bought the property for in 2019. That high price is emblematic of the high valuations of prime offic

  • IBM’s Red Hat Sued by Stephen Miller’s Legal Group for Anti-White Male Bias

    (Bloomberg Law) -- Ex-Trump adviser Stephen Miller’s legal group has sued IBM Corp. subsidiary Red Hat Inc. claiming the company’s diversity goals led to the discriminatory treatment and termination of a former White male employee. Most Read from BloombergMicrosoft’s Xbox Is Planning More Cuts After Studio ClosingsAmericans Are Racking Up ‘Phantom Debt’ That Wall Street Can’t TrackStormy Daniels Will Return to Court in Test of Trump’s DemeanorTrump Judge Indefinitely Postpones Documents Case Tri